Genmab has made further progress with its DuoBody™ technology platform by agreeing to collaborate with Johnson & Johnson’s Janssen Biotech to create and develop bispecific antibodies against multiple disease targets. Janssen will fund all research and Genmab will receive US$3.5 M upfront plus potential milestone and licence payments of up to US$175 M for each product successfully developed from the collaboration as well as royalties on sales of any commercialised products. Amgen’s US$1.16 B acquisition of Micromet in March 2012 fuelled industry interest in bispecific antibody technologies.